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Focal therapy has been introduced as an alternative treatment option for patients with unifocal, organ-confined prostate cancer (PCa) (1). The nature of this therapy is selective and lesion-based to preserve genitourinary function. Important structures that are spared 
include the neurovascular bundles, urethra, rectal wall, urethral sphincter, and bladder neck. 
The initial experience with focal therapy was derived from whole-gland cryotherapy and 
high-intensity focused ultrasound (HIFU) (2, 3). Over time, treatments became more le-
sion-based due to the increasing experience and improvements in multiparametric magnetic 
resonance imaging (mpMRI) (4). The feasibility of other ablative modalities were considered 
(e.g., radiofrequency ablation, focal brachytherapy) in light of new technologies such as pho-
todynamic therapy, laser interstitial thermotherapy, transurethral HIFU (TULSA) and irrevers-
ible electroporation (IRE) (5). Recently, Valerio et al. (5) reported the outcomes of 73 phase 
1-2 clinical trials on focal therapy. Their report established the feasibility and safety of focal 
therapy, demonstrating a low impact on genitourinary function and quality of life (QoL). 
However, there is a lack of evidence in evaluating focal therapy against PCa treatments 
that are currently in the guidelines. Similarly, there is a lack of consensus and data to deter-
mine which focal therapy modality is superior. Sivaraman and Barret (6) recently proposed 
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PURPOSE
We aimed to evaluate the genitourinary function and quality of life (QoL) following the ablation 
of different prostate segments with irreversible electroporation (IRE) for localized prostate can-
cer (PCa). 
METHODS
Sixty patients who received primary focal IRE for organ-confined PCa were recruited for this 
study. Patients were evaluated for genitourinary function and QoL per prostate segment treated 
(anterior vs. posterior, apex vs. base vs. apex-to-base, unilateral vs. bilateral). IRE system settings 
and patient characteristics were compared between patients with preserved vs. those with im-
paired erectile function and urinary continence. Data were prospectively collected at baseline, 
3, 6, and 12 months using the expanded prostate cancer index composite, American Urological 
Association symptom score, SF-12 physical and mental component summary surveys. Difference 
over time within segments per questionnaire was evaluated using the Wilcoxon’s signed rank 
test. Outcome differences between segments were assessed using covariance models. Baseline 
measurements included questionnaire scores, age, and prostate volume. 
RESULTS
There were no statistically significant changes over time for overall urinary (P = 0.07–0.89), bowel 
(P = 0.06–0.79), physical (P = 0.18–0.71) and mental (P = 0.45–0.94) QoL scores within each seg-
ment. Deterioration of sexual function scores was observed at 6 months within each segment 
(P = 0.001–0.16). There were no statistically significant differences in QoL scores between pros-
tate segments (P = 0.08–0.97). Older patients or those with poor baseline sexual function at time 
of treatment were associated with a greater risk of developing erectile dysfunction. 
CONCLUSION
IRE is a feasible modality for all prostate segments without any significantly different effect on 
the QoL outcomes. Older patients and those with poor sexual function need to be counseled 
regarding the risk of erectile dysfunction.
an alternative approach utilizing multiple 
ablative technologies: the “à la carte” ap-
proach. The authors advocated that rather 
than looking for a one-size-fits-all modality, 
a tailored solution to each individual pa-
tient depending on the PCa lesion localiza-
tion should be used. They argue that certain 
ablative modalities are better suited for le-
sions in certain prostate segments. In their 
experience; to preserve genitourinary func-
tion, posterior lesions are best treated with 
HIFU, anterior lesions with cryotherapy, and 
apical lesions with focal brachytherapy. At 
this point, their theoretical concept has not 
been validated in a clinical trial. More so, 
there are no studies on the performance of 
each of the available ablative systems on 
the different prostate segments in terms of 
oncologic control, genitourinary function 
or QoL. Studies on the system settings used 
during focal therapy and the dosimetry are 
also lacking. 
The initial feasibility trials with IRE demon-
strated the safety and feasibility of this new 
technique with low patient morbidity and 
good short-term oncologic control (7–12). 
IRE ablates tumor tissue by delivering a 
direct high-voltage current between a pair 
of needle electrodes (13). By targeting 
cells with multiple consecutive electrical 
pulses, the cell membrane becomes irre-
versibly permeable, resulting in cell death 
(13). However, there are no studies on the 
performance of IRE in the different prostate 
segments, in terms of oncologic control, 
genitourinary function and QoL. An IRE ab-
lation and resection study by Van den Bos 
et al. (14) showed that all the tissue within 
the needle configuration is ablated. Since 
all the prostate segments can be encom-
passed within the needle configurations of 
IRE, oncologic control should not theoreti-
cally differ between the prostate segments. 
Failures after IRE were recently proven to 
be significantly dependent on the applied 
safety margin and/or system errors that oc-
curred during the treatment (12).  
In this study, we evaluated the impact 
on the genitourinary function and QoL fol-
lowing the ablation of different prostate 
segments with IRE. In case of genitourinary 
functional failure, i.e., urinary incontinence 
requiring pads and/or erection insufficient 
for intercourse, patient characteristics and 
system settings were analyzed to assess po-
tential risk factors. 
Methods
Study design and patients
Patients treated between February 2013 
and August 2016 with primary IRE for local-
ized PCa were invited to have their genito-
urinary function and QoL evaluated. Pre-
treatment template mapping biopsies and 
mpMRI were used to diagnose PCa lesions 
and to identify prostate segments requiring 
treatment, in accordance with the selection 
guidelines (15). A total of 72 patients con-
sented for prospective evaluation, of which 
60 had at least 6 months of follow-up and 
were included for final retrospective anal-
ysis of prospectively acquired data (Table 
1). Data was collected at baseline, 3, 6, and 
12 months.  As outlined above, this analysis 
focused on the genitourinary function and 
QoL only but not on oncologic outcomes.
Ethical approval
The institutional review board of the 
Human Research Ethics Committee of the 
St. Vincent’s Hospital (Sydney, Australia) 
approved prospective collection of gen-
itourinary function and QoL data (HREC 
approval SVH 13/018). The data collection 
was executed in adherence to the declara-
tion of Helsinki (Fortealeza, Brazil, October 
2013) and written informed consent was 
obtained from all patients.
IRE procedure
Single-surgeon IRE was performed un-
der general anesthesia, antibiotic pro-
phylaxis, and deep-muscle relaxation. 
An indwelling catheter was placed prior 
to the procedure. Using the Nanoknife® 
system (AngioDynamics), four to six nee-
dle electrodes were placed with a trans-
perineal approach, encircling the tumor 
lesion. Needle placement was guided by 
biplanar transrectal ultrasound (BK med-
ical) and a floor mounted transperineal 
template grid. The needle locations and 
configuration geometry was recorded in 
the Nanoknife® system and operation re-
port. The inter-electrode distance ranged 
from 6 to 22 mm and the active tip length 
from 15 to 20  mm. Ten test pulses were 
delivered to evaluate the obtained di-
rect current with the standard applied 
voltages (~1500 V/cm). The remaining 
80 treatment pulses were delivered if an 
adequate current was achieved (20–40 
A); otherwise the applied voltage was 
altered until an adequate current was 
reached. The median minimum and 
maximum applied voltages were 1600 V 
(interquartile range [IQR], 1400–1760 V) 
and 2550 V (IQR, 2400–2850 V). The me-
dian minimum and maximum direct cur-
rents were 25 A (IQR, 20–28 A) and 43 A 
(IQR, 38–49 A). The pulse length was ini-
tially set at 70 μs (17 cases in total), but in-
creased to 90 μs to adhere to the interna-
tional treatment protocol proposed by the 
Clinical Research Office of the Endouro-
logical Society (CROES). The catheter was 
removed within 2–5 days depending on 
preexisting lower urinary tract symptoms.
Follow-up of genitourinary function 
and QoL
Genitourinary function and QoL data 
were prospectively evaluated using ques-
tionnaires at baseline, 3, 6, and 12 months. 
The expanded prostate cancer index com-
posite (EPIC) (16), American Urological As-
sociation (AUA) symptom score (17), short 
form of health survey (SF-12) physical and 
mental component summary surveys (18) 
were used for genitourinary and QoL eval-
uation. 
Segmental definitions and risk factor 
analysis
The prostate was segmentally divided 
into: 1) anterior (i.e., transition zone and 
fibromuscular stroma) vs. posterior (i.e., 
peripheral zone including anterior horn), 
2) apex (i.e., apex or apex to mid-apex) vs. 
base (i.e., base or base to mid-base) vs. 
apex-to-base (i.e., ablation from apex to 
base), and 3) unilateral vs. bilateral (i.e., 
unifocal ablation crossing the midline or 
multifocal bilateral ablation). The division 
into the different prostate segments is illus-
trated in the Figure. An ablation covering at 
least 80% of its total ablation zone volume 
in one segment was deemed a segmental 
ablation. The ablation zone volume was 
determined by perioperative needle con-
figuration and consisted of the area within 
the active needle configuration. For bilater-
Main points
• Focal irreversible electroporation for 
localized prostate cancer can be performed 
in all prostate segments without jeopardizing 
different quality of life outcomes.
• Older patients and those with poor baseline 
sexual function need to be counseled 
regarding the risk for erectile dysfunction.
• All men that were pad-free continent at 
baseline remained pad-free continent at 
their latest quality of life evaluation.
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al and apex-to-base ablations, 80% of the 
ablation zone volume covered both seg-
ments. Patients that had ablations covering 
multiple segments outside the specified 
segments were excluded from segmental 
analysis since potential interference was 
possible. 
For each individual segment, the 6-month 
questionnaire was used to assess changes 
on genitourinary function and QoL over 
time compared to baseline. Summary score 
differences from baseline and 6 months 
were used to assess the performance of IRE 
per prostate segment, correcting for base-
line age and prostate volume. In patients 
with genitourinary functional failure follow-
ing IRE treatment (i.e., urinary incontinence 
requiring pads and/or erections insuffi-
cient for intercourse), the standard system 
settings (interelectrode distance, voltage, 
amperage, pulse length) and patient char-
acteristics (age, prostate volume, baseline 
urinary/sexual function) were compared 
with patients without genitourinary func-
tional failure. As 6 patients did not answer 
the question (Q32) regarding erections suf-
ficient for intercourse in the 6-month ques-
tionnaire, despite completing the question-
naire, their answer to that question in their 
latest questionnaire (3 or 12 months) was 
used as a substitute.
Statistical analysis
The operational hypothesis of differ-
ences in genitourinary function and QoL 
between segments was tested by the anal-
ysis of covariance (ANCOVA) model. In this 
model, the dependent variable was the 
measured value at month 6, the indepen-
dent variable was the treatment group, and 
the covariate was the measured baseline 
value. All data were log-transformed prior 
to the analysis. This ANCOVA model was 
preferred to simpler methods such as the 
paired t-test, because by including baseline 
values in the modeling, it removes the po-
tential “regression toward the mean” effect. 
Post-hoc comparison between groups was 
conducted with the Tukey’s honest signifi-
cant difference test within the R statistical 
environment (R Development Core Team, 
2011) (19). The level of significance was set 
at P < 0.05.  
Results 
The study included 60 patients (median 
age, 67 years; IQR, 62–73 years) who under-
went IRE treatment. The median prostate 
specific antigen level was 5.9 μg/L (IQR, 
3.6–7.6 μg/L). In three patients, the ablation 
covered both the anterior and posterior 
segment and these patients were excluded 
for anterior vs. posterior segmental analy-
sis. Likewise, two patients received multi-
ple ablations interfering with apex vs. base 
vs. apex-to-base segmental analysis. Table 
1 summarizes the patient characteristics, 
including the number of patients per seg-
mental ablation. None of the patients start-
ed androgen deprivation therapy in the 
course of follow-up.
By the 6th month, no statistically signif-
icant deteriorations on the AUA symptom 
score (P = 0.17–0.89), EPIC urinary (P = 0.07–
0.88), EPIC bowel (P = 0.06–0.79) and both 
SF-12 physical (P  =  0.18–0.71) and mental 
(P = 0.45–0.94) scores were observed from 
baseline for each individually treated seg-
ment. For each segment, a significant de-
cline in the EPIC summary sexual score was 
found (P = 0.001–0.046), except for the bi-
lateral segment (P = 0.16) despite a decline 
within that segment (median decline from 
83 to 63). This decline on the EPIC sexual 
score would have been significant at 12 
months (P = 0.28) compared with baseline. 
None of the segments were significantly 
associated with better-preserved or deteri-
orated genitourinary function or QoL when 
the outcomes were compared with the op-
posite group (P = 0.08–0.97). In Tables 2–4 
the median summary scores per segment 
treated over time are presented. 
Figure. Schematic overview of the different prostate segments. (a) The anterior segment (beige) consists of the fibromuscular stroma with the transition 
zone. The posterior segment (red) consists of the peripheral zone, including the anterior horn of the transition zone. (b) The apical segment (red) includes 
any ablation performed within the mid to upper apex. The base segment (beige) is considered as any ablation in the area from the mid to the distal base. 
The apex-to-base segment included both the apex and base for more than 80% of the ablation zone volume. (c) A bilateral ablation was divided as an 
ablation that had more than 80% of the ablation zone volume in both the left and right hemi-prostate. Unilateral ablation was performed when more 
than 80% of the ablation occurred in either the left (beige) or right (red) hemi-prostate.
a b c
Table 1. Patient characteristics (n=60)
Variable Value
Age (years), mean±SD 68±7.0
PSA (μg/L), mean±SD 6.0±3.3
Prostate volume (cc), mean±SD 44±21









4+4 or higher 2 (3)








SD, standard deviation; PSA, prostate specific antigen.
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At baseline, 40 men (66%) had erections 
sufficient for intercourse, of whom 27 men 
(68%) maintained their erectile ability to 
have intercourse during the course of this 
study. Of these 27 men, the use of medicinal 
aids increased from 7.4% (2/27) at baseline 
to 18.5% (5/27) during the course of this 
study. Thirteen patients experienced an 
erectile function insufficient for intercourse 
following IRE. This was significantly associ-
ated with an older age at time of treatment 
(P  =  0.001) and a lower baseline sexual 
summary score on the EPIC questionnaire 
(P  =  0.002). None of the system settings 
were significantly associated with an in-
creased risk for genitourinary functional 
failure.  Table 5 displays the patient charac-
teristics, ablated segments and system set-
tings for patients with and without erectile 
dysfunction following IRE. 
Of the 58 men that were pad-free con-
tinent at baseline (97%, 58/60), only one 
patient needed one pad per day for urinary 
leakage at 6 months. The patient charac-
teristics or system parameters could not 
be statistically assessed due to the limited 
events of urinary incontinence. This patient 
was treated with a unilateral anterior abla-
tion, including the basal quadrant and did 
not differ from pad-free continent patients 
in terms of baseline age, prostate volume 
and EPIC urinary summary score. The uri-
nary continence of this patient improved at 
12 months. Therefore pad-free continence 
was preserved in all men at their latest QoL 
evaluation.
Discussion
This study showed that primary focal IRE 
could be safely performed on all prostate 
segments. There were no statistically sig-
nificant differences between prostate seg-
ments in terms of genitourinary function 
and QoL, indicating that this ablative mo-
dality is a feasible modality for any prostate 
segment. Apex-targeted IRE demonstrat-
ed improved bowel function on the EPIC 
questionnaire at 6 months compared with 
a decline in bowel function for base-target-
ed IRE. The clinical significance is negligi-
ble since both apex and base directed IRE 
treatments have remarkably high summa-
ry bowel scores at 6 months, and no clini-
cal symptoms were described (e.g., rectal 
pain, bleeding or fistula). There were no 
statistically significant QoL deteriorations 
at 6 months within the individual segments 
treated. However, sexual function was im-
paired for all segments at 6 months. This 
deterioration was not statistically signifi-
cant with bilateral IRE, which is most likely 
due to the limited number of patients in 
that group. A decline was observed on the 
EPIC sexual summary score over time that 
would have been significantly decreased at 
12 months compared with baseline. More-
over, there was some heterogeneity within 
the bilateral group that may have affected 
the outcomes. Most bilateral cases were sin-

















Different treatment impact 
Anterior vs. Posterior
AUA
Anterior 6 (3–14) 6 (3–11) 4 (3–10) 4 (2–5) No (P = 0.55) No (P = 0.97,
Posterior 6 (3–12) 7 (3–10) 5 (2–11) 4 (2–11) No (P = 0.19) E= -0.05, CI ±2.5)
EPIC urinary
Anterior 93 (72–98) 89 (69–96) 94 (79–98) 92 (82–97) No (P = 0.68) No (P = 0.83,
Posterior 89 (81–98) 92 (81–98) 92 (83–98) 94 (85–98) No (P = 0.24) E= -0.71, CI ±6.6)
EPIC sexual
Anterior 60 (25–82) 52 (29–71) 46 (14–79) 27 (2–79) Yes (P = 0.03) No (P = 0.41,
Posterior 67 (48–81) 47 (31–74) 49 (29–69) 42 (19–76) Yes (P = 0.008) E= -4.1, CI ±9.6)
EPIC bowel
Anterior 96 (92–100) 96 (93–98) 96 (91–99) 93 (87–99) No (P = 0.79) No (P = 0.80,
Posterior 96 (93–98) 96 (89–100) 96 (89–100) 97 (92–100) No (P = 0.70) E= 0.51, CI ±3.9)
SF-12 physical
Anterior 55 (44–56) 55 (48–56) 55 (40–57) 57 (43–58) No (P = 0.64) No (P = 0.74,
Posterior 56 (52–56) 55 (52–57) 55 (52–57) 55 (52–57) No (P = 0.35) E= -0.71, CI ±4.1)
SF-12 mental
Anterior 56 (39–58) 56 (50–58) 56 (40–60) 53 (48–60) No (P = 0.80) No (P = 0.64,
Posterior 56 (50–58) 57 (53–59) 56 (48–58) 57 (56–59) No (P = 0.45) E= 1.1, CI ±4.4)
Data are presented as median (interquartile range). 
AUA, American Urological Association; E, the effect size of anterior vs. posterior; CI, confidence interval (represents 47.5% deviation from the mean); EPIC, expanded prostate 
cancer index composite; SF-12, short form of health survey.
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gle-ablative IRE, targeting anterior midline 
lesions. However, multi-ablative bilateral 
ablations performed in three patients re-
sulted in two having erectile dysfunction. 
The more extensive ablative procedures in 
most bilateral cases may have led to the im-
proved urinary function scores at 6 months 
in this group due to post-treatment pros-
tate volume reduction (20).
Promising rates of preserved pad-free uri-
nary continence were found. It was demon-
strated that older patients at time of treat-
ment and those with poor baseline sexual 
function were significantly at risk of devel-
oping erections insufficient for intercourse. 
This may be unexpected since animal stud-
ies suggested that in pigs the endoneural 
architecture was preserved following IRE 
and showed signs of regeneration (21). In 
a preclinical study, it  was also shown in 
rat sciatic nerves that the number of my-
elinated axons and the thickness of myelin 
sheath were preserved at 10 weeks follow-
ing IRE exposure (22). None of the system 
settings used could be identified to be a sig-
nificant risk factor for erectile dysfunction. 
A prolonged pulse length showed a trend 
of significance, which could be explained 
by increased Joule-heating. It was shown in 
a polyacrylamide gel that applying longer 
pulses is associated with more Joule-heat-
ing and potentially more thermal damage 
due to higher energy delivery (23). Surpris-
ingly, erectile dysfunction also occurred 
in ablations that were far away from the 
neurovascular bundle, suggesting another 


































Apex 3 (2–16) 7 (3–10) 4 (2–12) 4 (2–8) No (P = 0.86) No (P = 0.79, No (P = 0.28, No (P = 0.41,
Base 10 (4–12) 10 (4–13) 7 (4–14) 8 (2–23) No (P = 0.89) E= 0.43, E= -1.5, E= 1.9,
Apex-to-Base 6 (4–14) 6 (3–11) 5 (3–10) 4 (3–5) No (P = 0.19) CI ±3.1) CI ±2.7) CI ±3.0)
EPIC urinary
Apex 96 (81–98) 94 (78–99) 96 (77–98) 94 (90–96) No (P = 0.88) No (P = 0.64, No (P = 0.34, No (P = 0.93,
Base 87 (78–94) 89 (74–96) 90 (84–97) 85 (70–98) No (P = 0.33) E= 2.0, (E= 3.4, E= -1.5,
Apex-to-Base 92 (77–98) 89 (72–98) 93 (84–98) 95 (89–98) No (P = 0.23) CI ±8.2) CI ±7.0) CI ±7.8)
EPIC sexual
Apex 67 (55–90) 54 (39–75) 53 (41–76) 48 (26–87) Yes (P = 0.008) No (P = 0.53, No (P = 0.91, No (P = 0.72,
Base 62 (49–76) 51 (36–74) 54 (23–73) 50 (8–72) Yes (P = 0.046) E= -3.7, E= 0.60, E= -4.3,
Apex-to-Base 60 (27–85) 42 (18–73) 41 (21–69) 35 (6–77) Yes (P = 0.001) CI ±11.6) CI ±10.1) CI ±11.0)
EPIC bowel
Apex 96 (91–98) 96 (94–100) 98 (96–100) 97 (94–100) No (P = 0.055) No (P = 0.08, No (P = 0.11, No (P = 0.93,
Base 97 (91–100) 93 (84–100) 93 (85–100) 86 (71–100) No (P = 0.44) E= -4.3, E= -3.5, E= -0.87,
Apex-to-Base 96 (91–100) 96 (91–99) 96 (89–98) 96 (91–100) No (P = 0.44) CI ±4.7) CI ±4.1) CI ±4.6)
SF-12 physical
Apex 56 (53–56) 55 (53–56) 56 (53–57) 55 (54–57) No (P = 0.53) No (P = 0.26, No (P = 0.63, No (P = 0.73,
Base 56 (52–58) 56 (47–57) 52 (40–57) 47 (44–56) No (P = 0.18) E= -2.9, E= -1.1, E= -1.9,
Apex-to-Base 54 (45–57) 55 (46–57) 56 (42–58) 56 (53–58) No (P = 0.71) CI ±5.0) CI ±4.3) CI ±4.8)
SF-12 mental
Apex 56 (52–58) 7 (54–58) 57 (54–58) 58 (57–59) No (P = 0.94) No (P = 0.94, No (P = 0.77, No (P = 0.94,
Base 57 (48–58) 56 (44–58) 56 (41–57) 48 (42–55) No (P = 0.66) E= -0.23, E= 0.73, E= -0.96,
Apex-to-Base 57 (44–59) 556 (50–59) 54 (45–59) 56 (49–60) No (P = 0.62) CI ±5.6) CI ±4.9) CI ±5.4)
Data are presented as median (interquartile range).
AUA, American Urological Association; E, effect size; CI, confidence interval; EPIC, expanded prostate cancer index composite; SF-12, short form of health survey.
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mechanism behind the observed decrease 
in sexual function that may be elucidated in 
larger datasets. Future in vivo studies must 
provide the ideal system settings to suc-
cessfully ablate prostate tissue while mini-
mizing Joule-heating. 
Our study is limited we did not include 
any data on oncologic performance. We 
choose to exclude the oncologic control per 
prostate segment based on previous results 
from an ablation and resection study (14). 
Moreover, infield oncologic failures follow-
ing IRE were proven to be significantly de-
pendent on the applied safety margin and/
or system errors occurring during IRE (12). 
In this cohort, 7 patients had infield residual 
disease, including all different prostate seg-
ments (anterior, posterior, apex, mid, base), 
justifying our exclusion of oncologic anal-
ysis. Other limitations are the small cohort 
size and the short follow-up time. Murray et 
al. (8) showed that (marginal) improvement 
of erectile function was seen between 6–12 
months, which may be applicable to our 
results. Furthermore, division of ablations 
into true segmental ablations can be arbi-
trary. An ablation was deemed segmental 
if an estimated 80% of its ablation volume 
(volume between electrodes) occurred in 
one segment. It has been shown that the 
histopathologic ablation zone extends 
the needle configuration by 2.5–2.9 times 
(two-dimensionally) (24). Moreover, in our 
institution, a T2-weighted MRI was per-
formed 1 week after IRE to confirm if the 
predefined treatment region was covered 
by IRE. The coverage often extended the 
needle configuration, potentially invading 
other segments. The ablation zone volume 
on T2-weighted MRI has been shown to 
closely correlate with the volume on his-
topathology (25). However, this correlation 
was performed at 4 weeks after IRE, and the 
swelling and edema seen on T2-weighted 
MRI at 1 week can easily obscure  the his-
topathologic effect. We aimed to reduce 
the extended ablation effect by using the 
exact needle locations/geometry regis-
tered in the Nanoknife® system and surgical 
report. Although the ablation zone dimen-
sions may invade into other segments, we 
showed that wherever the electrodes were 
placed, good genitourinary function and 
QoL could be obtained. Interestingly, some 
ablations included the urethra or extended 
the capsule, without causing significant 
side effects seen with other ablative modal-
ities (e.g., urethral sloughing with cryother-
apy) (26).
In conclusion, IRE can be safely performed 
in each prostate segment without significant-
ly different effects on genitourinary function 
and QoL outcomes, establishing this tech-
nique as a feasible focal ablative modality 
with good functional outcomes for all pros-
tate segments treated. Patients who were 
























Unilateral 6 (3–13) 7 (3–11) 6 (2–11) 4 (2–9) No (P = 0.17) No (P = 0.75,
Bilateral 11 (4–13) 5 (2–12) 4 (3–14) 5 (4–13) No (P = 0.25) E= -0.71, CI ±6.6)
EPIC urinary
Unilateral 92 (80–98) 91 (77–98) 93 (81–98) 94 (92–98) No (P = 0.46) No (P = 0.084,
Bilateral 84 (76–95) 88 (70–94) 95 (90–99) 88 (79–94) No (P = 0.068) E= 7.4, CI ±8.3)
EPIC sexual
Unilateral 62 (45–79) 47 (31–72) 43 (26–69) 38 (15–77) Yes (P < 0.001) No (P = 0.54,
Bilateral 83 (63–90) 41 (21–76) 63 (37–84) 59 (28–77) No (P = 0.16) E= 3.8, CI ±12.0)
EPIC bowel
Unilateral 96 (93–98) 96 (91–100) 96 (91–100) 98 (93–100) No (P = 0.67) No (P = 0.62,
Bilateral 95 (89–96) 96 (90–98) 93 (86–96) 93 (82–97) No (P = 0.31) E= -1.3, CI ±5.1)
SF-12 physical
Unilateral 56 (45–57) 55 (50–57) 56 (51–57) 56 (53–57) No (P = 0.63) No (P = 0.31,
Bilateral 55 (48–56) 55 (49–57) 54 (49–57) 51 (44–56) No (P = 0.40) E= 2.6, CI ±4.9)
SF-12 mental
Unilateral 57 (49–58) 57 (51–58) 56 (48–58) 57 (55–59) No (P = 0.46) No (P = 0.94,
Bilateral 58 (43–60) 56 (46–59) 56 (49–60) 58 (49–61) No (P = 0.61) E= 0.21, CI ±5.5)
Data are presented as median (interquartile range).
AUA, American Urological Association;  E, the effect size of bilateral vs. unilateral; CI, confidence interval (47.5% deviation from the mean); EPIC, expanded prostate cancer 
index composite; SF-12, short form of health survey.
Genitourinary function and QoL after IRE of prostate segments • 273
older at time of treatment, or those with a 
poor baseline sexual function, had higher risk 
to develop erectile dysfunction. Future com-
parative trials need to elucidate whether the 
trifecta outcomes of focal therapy supersedes 
those of current radical treatments.
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